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Abstract Testicular tumors and their treatment interfere
with homeostasis, hormonal status included. The aim of the
study was to evaluate hormonal disorders of the pituitary–
gonadal axis in men treated for testicular tumors. One
hundred twenty-eight men treated for a unilateral testicular
tumor at our institution were included. The hormonal status
was prospectively evaluated in 62 patients before
orchiectomy, 120 patients 1 month after orchiectomy and
110 patients at least 1 year after the treatment. The con-
centrations of human chorionic gonadotropin (hCG),
testosterone (T), estradiol, luteinizing hormone (LH), fol-
licle-stimulating hormone (FSH) and prolactin were mea-
sured. The clinically significant testosterone deficiency was
defined either as testosterone\2.31 ng/mL or testosterone
within the range of 2.31–3.46 ng/mL but simultaneous with
T/LH ratio B1. Changes in hormone levels were signifi-
cant: LH and FSH rose in the course of observation, and the
concentration of hCG, testosterone, estradiol decreased.
PRL concentration was the lowest at 1 month after
orchiectomy. In multivariate analysis, the risk of the clin-
ically significant testosterone deficiency was 0.2107 (95%
CI 0.1206–0.3419) prior to orchiectomy, 0.3894 (95% CI
0.2983–0.4889) 1 month after surgery and 0.4972 (95% CI
0.3951–0.5995) 1 year after the treatment. The estradiol
concentration was elevated in 40% of patients with recently
diagnosed testicular cancer and that was correlated with a
higher risk of testosterone deficiency after the treatment
completion. Hormonal disorders of the pituitary–gonadal
axis in men treated for testicular tumors are frequent. The
malignant tissue triggers paraneoplastic disorders that
additionally disturb the hormonal equilibrium.
Keywords Testicular tumor  Orchiectomy  Testosterone 
Hormones
Introduction
Affecting mostly Caucasian males aged 15–40, testicular
germ cell tumors represent the most common malignancy in
this age group. Presenting symptoms usually include a tes-
ticular mass as well as lesions along the body mid-line (i.e.,
retroperitoneum, mediastinum or brain). Clinically divided
into seminomas and non-seminomas, each group accounting
for approximately 50%, they are a fine example of success in
oncology. The prognosis remains excellent, especially in
testicle-limited (stage I) tumors. Overall survival rates reach
99% for stage I seminomas. On the other hand, metastatic or
relapsed disease does not preclude radical approach and
chances for cure. Even in the ‘poor prognosis’ group of
metastatic non-seminoma, 48–60% can still be cured with
first-line chemotherapy [1]. Also older patients ([65 years)
with germ cell tumors, believed to have a worse prognosis,
achieve a survival rate as high as 72–83% [2]. Often com-
bined with surgery and radiotherapy, chemotherapy has been
the cornerstone of the treatment. New approaches such as
high-dose chemotherapy with autologous stem cell transplant
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are being investigated to increase the survival rates in poor
prognosis patients. Nevertheless, the clinical importance has
now shifted from pursuing optimal treatment methods to
closer follow-up of cancer survivors and an early diagnosis of
late toxicities. As many as 24% of testicular cancer survivors
develop overweight, 24%—hypercholesterolemia—and
30%—hypertension. Survivors with testosterone levels
\4.3 ng/mL (22%) have an increased risk of the metabolic
syndrome [3]. This effect is now attributed to the cumulative
dose of cisplatin [4]. Uncompensated hypogonadism is
characterized by the testosterone concentration below the
lower limit of normal. In compensated hypogonadism, the
testosterone concentration is within normal range, while the
LH concentration exceeds the upper limit of normal.
Impaired post-pubertal androgen function may cause infer-
tility, sexual disorders, muscle weakness and bone dem-
ineralisation, as well as other metabolic disorders, depression
and cognitive impairment [5, 6]. Male hypogonadism is
defined as a syndrome of clinical symptoms resulting from
androgen deficiency. It stems either from impaired function
of the gonads (primary hypogonadism) or from hypothala-
mic–pituitary disorders at different levels (secondary
hypogonadism). The most common causes of the primary
hypogonadism are Klinefelter syndrome and testicular
tumors [7–9]. The diagnosis of clinically significant testos-
terone (T) deficiency based solely on the total testosterone
concentration is problematic. Total testosterone must exceed
3.50–4.00 ng/dL to reliably predict normal free testosterone
[10]. According to the recommendations published in 2009 to
be used in clinical practice, men with total serum of testos-
terone \2.31 ng/mL (8 mmol/L) should be treated with
hormone replacement therapy. For men with total testos-
terone values between 2.31 and 3.46 ng/mL (8 and 12 mmol/
L), treatment should be considered in the presence of
symptoms associated with testosterone deficiency [11]. T
(ng/mL)/LH (mIU/mL) ratio can facilitate the decision in
men with borderline testosterone. The ratio reflects the
complex nature of testosterone deficiency in adulthood that
originates from hypothalamic–pituitary–gonadal axis distur-
bances. The T/LH ratio B1 correlates with the presence of
testosterone deficiency symptoms [12]. Knowledge of hor-
monal disorders in patients treated for testicular tumor will
allow to predict and possibly avoid metabolic consequences
of hypogonadism. The aim of the paper is to evaluate the
dynamics of hormonal changes in the pituitary–gonadal axis
in adult men treated for testicular tumors.
Materials and methods
One hundred twenty-eight patients with a unilateral tes-
ticular tumor were included in the study. The procedures
had been approved by the Ethical Committee of Maria
Sklodowska-Curie Memorial Cancer Center and Institute
of Oncology, Warsaw, Poland.
The study was prospective, non-interventional. Written
informed consent was obtained from each patient.
The study procedures were carried out at three control
points:
• directly before orchiectomy (if the patient was referred
prior to surgery),
• one month after orchiectomy,
• at least 1 year after the completion of treatment.
Patients with progressive disease after the first-line
treatment were excluded from the analysis at control
points 2 and 3.
The data were collected at Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, War-
saw, Poland, between 2009 and 2013. Taking into account
the patients lost to follow-up, control point procedures
were conducted 292 times: 62 times for the first control
point, 120 for the second and 110 for the third one. In
multivariate analyses, five stage I patients progressing after
the completion of the second control point procedures were
excluded due to possible disturbing effect of the recur-
rence. Characteristics of the clinical data are presented in
Table 1. One month after orchiectomy, the patients were
divided into two groups: with or without active disease. At
control points, the patients had their blood drawn during
routine visits. The plan was to assess the pituitary–gonadal
axis hormones, i.e., LH (normal values: 1.7–8.6 mIU/mL),
FSH (normal values: 1.5–12.4 mIU/mL), testosterone
(normal values: 3.47–8 ng/mL), as well as those potentially
affecting the axis, i.e., estradiol (normal values:
7.6–42.6 pg/mL), prolactin (normal values: 4.6–21.4 ng/
mL) and beta-hCG (normal values: \5 mIU/mL), testos-
terone (normal values: 3.47–8.0 ng/mL). It was decided to
recognize testosterone deficiency at values \2.31 ng/mL
(8 mmol/l). The gray zone consisted of patients with
testosterone values of 2.31–3.46 ng/ml (8–12 mmol/l). For
the gray zone, the clinically significant testosterone defi-
ciency was diagnosed if the T/LH ratio was B1. Changes in
the hormone concentrations were analyzed at the above-
mentioned control points. The reactivity of Leydig cells to
stimuli from the pituitary gland was evaluated on the basis
of T/LH ratio. Associations between hormone concentra-
tions at the planned control points were analyzed. We used
the general linear model (GLM) and logarithmic transfor-
mation to evaluate changes in hormone concentrations. In
the multivariate generalized linear mixed models, data are
organized according to the random factors. The mixed
effect models could therefore recover information in the
data not found by the traditional methods, especially for
incomplete or unbalanced data. Percentage changes were
addressed by using a log-transformation in the models as a
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link functions. To overcome the problem with outliers the
gamma distribution was used. Log scale in the pictures is a
consequence of log links introduced in the models.
Dichotomous parameters were analyzed by the ‘logit’
linking function. Moreover, the models comprised con-
founding factors, e.g., age and clinical stage. The calcula-
tions were carried out with GLIMMIX procedure in the
SAS software (version 12.3). In the analysis of hormone
levels, we used Pearson’s linear correlation coefficient. The
correlation was considered strong with coefficient values
[0.5 for positive correlations and \-0.5 for negative
correlations. The results were considered statistically sig-
nificant at p\ 0.05.
Results
Changes in hormone concentrations over time
The concentrations of both pituitary gonadotropins, LH and
FSH, increased significantly at subsequent control points,
not only directly after orchiectomy. In the course of
treatment, the concentration of tumor gonadotropin, hCG,
decreased and returned to normal in all patients within
1 year after the completion of treatment. We observed a
significant decrease in testosterone concentration directly
after orchiectomy. One year after the treatment, testos-
terone concentrations still remained significantly lower
than before orchiectomy. 40% of patients with active dis-
ease presented with pathologically high estradiol concen-
trations, exceeding the normal range even 50-fold.
However, the estrogen concentrations were decreasing
significantly during treatment. Additionally, a statistically
significant decrease in prolactin concentrations was
observed directly after orchiectomy. Similarly, these values
returned to normal 1 year after completion of the anti-
cancer treatment. Table 2 shows concentrations of the
hormones analyzed at a given control point. Figure 1
shows these results graphically.
The risk of testosterone deficiency
In the presented group of patients, testosterone concentra-
tion below 2.31 ng/mL was found in 5% of patients prior to
orchiectomy, 16% of patients a month after orchiectomy
and 17% of patients at least 1 year after curative treatment.
The values of testosterone between 2.31 and 3.46 ng/mL
were detected in 17% of patients at the first control point,
27% of patients in the second and 30% of patients in the
third control point. After taking into account the T/LH ratio
B1, the clinically significant testosterone deficiency was
diagnosed at three successive checkpoints in additional 12,
23 and 29% of patients. In the multivariate analysis, taking
into account the clinical stage and the patient’s age, it was
found that the risk of clinically relevant testosterone defi-
ciency was 0.2107 before orchiectomy (95% CI
0.1206–0.3419), 0.3894 one month after orchiectomy (95%
CI 0.2983–0.4889) and 0.4972 one year after curative
treatment (95% CI 0.3951–0.5995). The risk of clinically
significant testosterone deficiency at the second and the
third control points was higher than in the first one. That
difference was statistically significant (p = 0.0121 and
p = 0.0005, respectively). Patients treated for testicular
tumors proved to present with lowered testosterone/LH
ratio, which was aggravating over time and statistically
significant—Fig. 2.
Table 1 Characteristics of the study group
Participants 128 men
Patients’ age
(median)
18–63 years
(31 years)
Analyzed
First control point 62 patients
Second control point 120 patients
Third control point 110 patients
Histology of the primary testicular tumor
Seminoma 59 patients
Non-seminoma 67 patients
Seminoma component present 14 patients
Ca. embryonale component present 56 patients
Choriocarcinoma component present 12 patients
Yolk sac tumor component present 27 patients
Teratoma immaturum component present 12 patients
Teratoma maturum component present 22 patients
Leydig cell tumor 2 patients
Clinical stage
IA 59 patients
IB 15 patients
IS 5 patients
IIA 16 patients
IIB 2 patients
IIC 2 patients
IIIA 13 patients
IIIB 8 patients
IIIC 8 patients
Treatment methods
Unilateral orchiectomy 128 patients
Chemotherapy 70 patients
Radiotherapy 16 patients
Retroperitoneal lymph node dissection 11 patients
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Table 2 Hormone concentrations at control points
Control point Minimum Maximum Median Number of patients with
values above normal limits
Number of patients with
values below normal limits
Chorionic gonadotropin (mIU/mL)
1. 0 533.390 1.95 26/62
(42%)
0
2. 0.1 549.893 0.1 23/120
(19%)
0
3. 0.1 4.1 0.1 0/110 0
Prolactin (ng/mL)
1. 3.80 34.60 8.55 2/58
(4%)
2/58
(3%)
2. 2.80 21.90 7.6 1/117
(1%)
15/117
(13%)
3. 3.55 21.1 9.7 0/110 4/110
(3%)
Estradiol (pg/mL)
1. 5.00 2228.00 34.2 22/57
(39%)
1/57
(2%)
2. 4.00 2333.00 27.00 18/115
(16%)
2/115
(2%)
3. 5.00 101.70 22.91 7/110
(6%)
9/110
(8%)
Follicle-stimulating hormone (mIU/mL)
1. 0.10 29.40 4.96 6/58
(10%)
22/58
(38%)
2. 0.10 58.40 11.1 37/120
(31%)
18/120
(15%)
3. 0.20 66.31 16.79 55/110
(50%)
3/110
(3%)
Luteinizing hormone (mIU/mL)
1. 0.10 13.70 2.9 5/58
(9%)
23/58
(40%)
2. 0.10 27.20 6.51 /120
(%)
18/120
(15%)
3. 0.10 135.00 7.01 43/110
(39%)
4/110
(4%)
Testosterone (ng/mL)
1. 1.10 15.00 5.05 12/58
(21%)
\2.31: 3/58
(5%)
C2.31 and B3.46: 10/58
(17%)
2. 0.60 10.30 3.8 6/120
(5%)
\2.31: 19/120
(16%)
C2.31 and B3.46: 32/120
(27%)
3. 1.30 12.00 3.59 2/110
(2%)
\2.31: 19/110
(17%)
C2.31 and B3.46: 33/110
(30%)
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The correlation between hormone concentrations
A strong negative correlation was found between beta-hCG
concentration and both pituitary gonadotropins in patients
with active disease. In these patients, estradiol concentra-
tion was negatively correlated with LH and FSH concen-
trations, whereas beta-hCG was positively correlated with
testosterone (before orchiectomy) and prolactin concen-
trations. These associations were statistically significant.
Estradiol concentrations correlated positively with
prolactin concentrations in this group of patients. Such
correlations are not present in the group of patients free of
disease. The findings are shown in Table 3. In multivariate
analysis, taking into account patients age, clinical stage as
well as the concentrations of chorionic gonadotropin and
estradiol a month after orchiectomy, it was demonstrated
that elevated estradiol predicted clinically relevant testos-
terone deficiency (p = 0.0288) after treatment completion.
The effect of high concentrations of beta-hCG was not
statistically significant (p = 0.0777).
Fig. 1 Changes in hormone concentrations at control points (logarithmic transformation)
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Discussion
It has been estimated that the annual decrease in the cir-
culating testosterone concentration is 0.2–2.0%. The per-
centage of middle-aged men presenting with hypogonadism
is 6% [13]. In comparison, patients treated for a testicular
malignancy performed worse. According to the literature,
the risk of decreased testosterone concentration many years
after a successful treatment of testicular tumors is 5–25%
[8, 9, 14–20]. In contrast, it has also been reported that
10 years after orchiectomy testosterone concentrations do
not differ from those in control groups [8]. All authors
[8, 9, 14–20] agree that chronic compensated hypogo-
nadism continues to be an issue even over 10 years after
the completion of treatment [8]. According to otherFig. 2 Testosterone/LH ratio at control points
Table 3 Correlations between
concentrations of hormones
associated with the pituitary–
gonadal axis
LH FSH Testosterone Estradiol HCG PRL
Active disease
First control point—before orchiectomy
LH 1.0 0.92393 20.63824 20.64714 20.67406 20.36690
FSH 0.92393 1.0 20.64079 20.79251 20.72811 20.48402
Testosterone 20.63824 20.64079 1.0 0.63215 0.62279 0.40277
Estradiol 20.64714 20.79251 0.63215 1.0 0.84003 0.66343
HCG 20.67406 20.72811 0.62279 0.84003 1.0 0.56137
PRL 20.36690 20.48402 0.40277 0.66343 0.56137 1.0
Second control point—1 month after orchiectomy—patients with active disease
LH 1.0 0.93580 20.25795 20.51236 20.65898 20.28004
FSH 0.93580 1.0 20.38360 20.63227 20.75261 20.30979
Testosterone 20.25795 20.38360 1.0 0.61473 0.35639 0.30749
Estradiol 20.51236 20.63227 0.61473 1.0 0.68578 0.30295
HCG 20.65898 20.75261 0.35639 0.68578 1.0 0.25110
PRL 20.28004 20.30979 0.30749 0.69001 0.25110 1.0
Free of disease
Second control point—1 month after orchiectomy—patients free of disease
LH 1.0 0.83210 20.09518 20.31178 20.47824 20.05733
FSH 0.83210 1.0 20.13473 20.30350 20.47802 20.10608
Testosterone 20.09518 20.13473 1.0 0.24555 0.12947 0.03140
Estradiol 20.31178 20.30350 0.24555 1.0 0.42551 0.14004
HCG 20.47824 20.47802 0.12947 0.42551 1.0 0.22823
PRL 20.05733 20.10608 0.03140 0.14004 0.22823 1.0
Third control point—1 year after treatment completion
LH 1.0 0.83956 20.12871 20.19528 0.06883 0.08902
FSH 0.83956 1.0 20.18038 20.21381 0.09891 0.04118
Testosterone 20.12871 20.18038 1.0 0.52583 20.11595 0.24094
Estradiol 20.19528 20.21381 0.52583 1.0 20.20111 0.07692
HCG 0.06883 0.09891 20.11595 20.20111 1.0 0.14737
PRL 0.08902 0.04118 0.24094 0.07692 0.14737 1.0
Bold font indicates strong and very strong correlations, for all p\ 0.0001
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investigators, 24–75% of patients present with abnormal
LH concentrations many years after the anticancer treat-
ment. In addition, the upper range of the values given above
seems to be better documented [16, 18–20]. In the presented
material, the risk of pituitary-Leydig cell axis insufficiency
increased over time, even after the completion of treatment.
Moreover, the LH concentration seems to better reflect
hormonal changes in men years after unilateral orchiectomy
[8, 21]. The lowered testosterone/LH concentration ratio
directly after orchiectomy may be a sign of a decrease in
volume of the testosterone-releasing tissue after an LH
stimulus. However, the subsequent decrease in this ratio
should rather be interpreted as a decreased reactivity of
Leydig cells in response to LH stimulation. This finding is
confirmed by other authors [8, 21]. Luteinizing hormone
and chorionic gonadotropin are morphologically similar
polypeptide hormones stimulating the same receptor [22].
This fact explains the disruptive effect of high beta-hCG
concentrations on the pituitary–gonadal axis. Other authors
also suggest that hCG concentrations in testicular cancer
patients correlate with testosterone, prolactin, estradiol and
gonadotropins concentrations [23–25]. In our study, nearly
40% of the patients with active disease presented with
elevated estradiol concentrations. In contrast, estradiol
concentrations exceeded the normal limits in only 7% of
patients without active disease. In the former group, we
found a very strong correlation between the elevated
estradiol concentrations and high beta-hCG concentrations.
This justifies the statement that estradiol fulfills the criteria
of a serum marker of the malignancy. According to other
authors, an increasing estradiol concentration may predict a
recurrence, even when other tumor markers remain within
normal limits [26]. However, the role of estradiol as a tumor
marker is still undetermined. Pathologically high estradiol
concentrations interfere with the pituitary–gonadal axis, as
confirmed by other authors [27, 28]. In the presented group
of patients, abnormally high estradiol concentrations in the
course of the disease were shown to have long-term con-
sequences, increasing the risk of testosterone deficiency
after treatment completion. The source of such high estra-
diol concentrations in patients with testicular tumors is
unclear. There have been scarce data that estradiol may be
secreted directly by the tumor, when exposed to chorionic
gonadotropin [29, 30]. Another potential source of estradiol
may be Leydig cells, stimulated by high hCG concentra-
tions [30].
In our material, prolactin concentrations also changed
significantly over time; this leads to a conclusion that
prolactin balance is disrupted in patients with testicular
tumors. Moreover, the balance is strongly dependent on
hCG and estradiol concentrations, which has been con-
firmed in other papers [31]. The changes in hormone
concentrations cannot be attributed only to unilateral
orchiectomy. The clinical picture suggests that the tumor
tissue also plays an important role in the endocrine
balance through the paraneoplastic mechanism. Hypogo-
nadism is a common problem in testicular cancer sur-
vivors. Yet, the need and principles of hormone
supplementation are still to be established in further
studies.
The study was limited by the fact that some of the
patients were lost to follow-up. Similarly, the small number
of patients included prior to orchiectomy could reduce the
study’s power.
Conclusions
Changes in hormone concentrations in men treated for a
unilateral testicular tumor are significant: LH and FSH
concentrations increase in the course of treatment, while
the concentrations of hCG, testosterone, estradiol decrease.
Prolactin is the lowest at 1 month after orchiectomy.
Pathologically high concentrations of chorionic gonado-
tropin and estradiol in these patients interfere with the
pituitary–gonadal axis in a paraneoplastic mode.
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